Eli Lilly is trading down 1.2% today as investors adopt a cautious stance ahead of the highly anticipated April FDA ruling on the company's oral obesity drug, Orforglipron. This volatility is compounded by ongoing market anxiety regarding the long-term sustainability of the GLP-1 market, following recent studies highlighting potential cardiovascular risks associated with ending such treatments. While the stock has seen positive sentiment regarding expanded access to Zepbound, the current price action reflects a broader trend of sluggishness in the obesity drug sector as the market awaits further regulatory clarity.
Click any event to see why LLY moved that day
No significant catalyst events detected.